Advertising for medical research funds

The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults.

Vaccine·2026

Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.

The Journal of infection·2025

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.

The Journal of infection·2024

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.

The Journal of infection·2024

Risk, regulation and offshore windfarms: Ways to manage environmental uncertainty and over-precaution.

Marine pollution bulletin·2024

Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO).

Trials·2023

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

Development and implementation of a rapid surveillance system for tobacco product retail availability in six U.S. sites.

Preventive medicine reports·2026

Commercial tobacco retail marketing in rural communities in Appalachian Kentucky, 2024.

Preventive medicine reports·2026

Association Between FDA Drug Recall Classification and Product-Related Characteristics.

Therapeutic innovation & regulatory science·2026

"Do you guys tell anybody?": Exploring allocation and implementation of opioid settlement funds and reduced access to health vending machines for people who use drugs.

Journal of studies on alcohol and drugs·2026

"Getting every smoker to participate and quit - GEMPAQ V2.0", a personalised smoking cessation smartphone app in Malaysia: A pilot randomised controlled trial.

Digital health·2026

Weight Loss Outcomes Among MyFitnessPal Users: Behavioral and Dietary Predictors of Success.

Nutrients·2026

Related Experiment Videos

Advertising for medical research funds

Related Concept Videos

The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults.

Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.

Risk, regulation and offshore windfarms: Ways to manage environmental uncertainty and over-precaution.

Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO).

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Development and implementation of a rapid surveillance system for tobacco product retail availability in six U.S. sites.

Commercial tobacco retail marketing in rural communities in Appalachian Kentucky, 2024.

Association Between FDA Drug Recall Classification and Product-Related Characteristics.

"Do you guys tell anybody?": Exploring allocation and implementation of opioid settlement funds and reduced access to health vending machines for people who use drugs.

"Getting every smoker to participate and quit - GEMPAQ V2.0", a personalised smoking cessation smartphone app in Malaysia: A pilot randomised controlled trial.

Weight Loss Outcomes Among MyFitnessPal Users: Behavioral and Dietary Predictors of Success.

Related Experiment Videos

Advertising for medical research funds

Related Concept Videos

Related Articles